Flag of the European Union EU Clinical Trials Register Help

Clinical trials for USAN

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    63 result(s) found for: USAN. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2008-005288-33 Sponsor Protocol Number: EMI111784 Start Date*: 2008-12-18
    Sponsor Name:GlaxoSmithKline Research & Development, LtdD
    Full Title: Methodology Study to develop Sinerem enhanced 3T MR Imaging of Atherosclerotic Plaques within the Carotid Arteries, and to compare Sinerem MRI to contrast enhanced ultrasound
    Medical condition: Atherosclerotic plaque within the carotid artery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-007762-39 Sponsor Protocol Number: IL1T-GA-0816 Start Date*: 2009-09-23
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Rilonacept for the Prophylaxis of Gout Flares During the Initiation of Allopurinol Therapy
    Medical condition: Gout flare
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064900 Gout flare LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022247-37 Sponsor Protocol Number: BDP-GVHD-03 Start Date*: 2010-11-24
    Sponsor Name:Soligenix, Inc.
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF ORBEC® (ORAL BECLOMETHASONE 17,21-DIPROPIONATE) IN CONJUNCTION WITH TEN DAYS OF HIGH-DOSE P...
    Medical condition: Patients with acute gastrointestinal Graft Versus Host Disease.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064677 Graft versus host disease in intestine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003241-15 Sponsor Protocol Number: SCH/12/043 Start Date*: 2012-10-09
    Sponsor Name:Sheffield Children's NHS Foundation Trust
    Full Title: NeSST2: A multi-stage clinical study to develop a non-invasive Short Synacthen Test (SST) with nasally administered Synacthen and salivary cortisol. The validated non-invasive SST will be used to e...
    Medical condition: In stages 1+2 of the study healthy volunteers will be used to determine the bioequivalence of nasal Synacthen with 1 microgram of intravenous synacthen. Stage 3 will use healthy children to establi...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064973 Allergic bronchospasm LLT
    15.0 10014698 - Endocrine disorders 10001367 Adrenal insufficiency PT
    Population Age: Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001579-30 Sponsor Protocol Number: TV5600-CNS-20006 Start Date*: 2014-11-27
    Sponsor Name:Teva Pharmaceutical Industries Ltd.
    Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (...
    Medical condition: Primary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10063401 Primary progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001310-32 Sponsor Protocol Number: 2006444 Start Date*: 2006-06-16
    Sponsor Name:Procter & Gamble Technical Centres Limited
    Full Title: A double-blind, randomized, 6-week, parallel-group clinical trial to assess the safety and efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet)...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009900
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) CZ (Completed) HU (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-003433-33 Sponsor Protocol Number: 8669-060 Start Date*: 2011-07-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Single Dose Biocomparison Study to Assess two Pediatric Formulations of MK-8669 to the Provisional Market Formulation in Healthy Subjects
    Medical condition: Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006008 Bone sarcoma NOS LLT
    Population Age: Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005897-54 Sponsor Protocol Number: S241-GB-08 Start Date*: 2006-02-01
    Sponsor Name:Stiefel Laboratories Maidenhead Ltd
    Full Title: A Phase 1, Single-Centre, Single-blind, CPO Solution Human Patch Test in Healthy Subjects
    Medical condition: Not Applicable (Healthy Volunteer Study)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004417-15 Sponsor Protocol Number: DEV/ASP/00645.2006 Start Date*: 2006-04-18
    Sponsor Name:UCB Pharma Ltd
    Full Title: Single center, therapeutic exploratory clinical trial to evaluate the safety of sodium oxybate (Xyrem) 500 mg/mL oral solution on potential endocrine changes at currently labeled therapeutic dose r...
    Medical condition: Cataplexy in adult patients with narcolepsy
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002367-24 Sponsor Protocol Number: PC TA001/04 Start Date*: 2004-10-20
    Sponsor Name:PhotoCure ASA
    Full Title: A blinded, prospective, randomised, placebo-controlled, multi-centre, split-face study of photodynamic therapy with Metvix 160 mg/g cream in subjects with acne vulgaris.
    Medical condition: Moderate inflammatory acne vulgaris.
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005015-13 Sponsor Protocol Number: PC T405/05 Start Date*: 2006-02-16
    Sponsor Name:PhotoCure ASA
    Full Title: A multicenter, double blind, vehicle-controlled, randomized study of photodynamic therapy (PDT) with Metvix®160 mg/g cream and Aktilite CL128 LED light in patients with multiple actinic keratoses o...
    Medical condition: actinic keratosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002343-29 Sponsor Protocol Number: CRCSV2A18 Start Date*: 2020-08-11
    Sponsor Name:Service of Neurology, CHU Liege
    Full Title: Synaptic modifications in subjective cognitive decline. A study using [18F]UCB-H, a synaptic vesicle 2A radiotracer.
    Medical condition: Neurodegenerative Cognitive Disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10048598 Cognitive disorders LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-007057-42 Sponsor Protocol Number: A4M108119 Start Date*: 2007-05-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: An open-label study of leukocyte counts in the cerebrospinal fluid and blood of subjects with relapsing forms of multiple sclerosis following treatment with firategrast
    Medical condition: relapsing forms of multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000366-36 Sponsor Protocol Number: TLK286.3025 Start Date*: 2006-06-07
    Sponsor Name:Telik, Inc.
    Full Title: Phase 3 randomized study of TLK286 (Telcyta™) in combination with liposomal doxorubicin (Doxil®/Caelyx®) versus liposomal doxorubicin (Doxil®/Caelyx®) as second-line therapy in platinum refractory ...
    Medical condition: platinum refractory or resistant ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033160 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002633-20 Sponsor Protocol Number: A4M105038 Start Date*: 2006-11-17
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Six Months' Administration of Firategrast (150 – 1200mg twice dail...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) FI (Completed) FR (Completed) AT (Completed) IT (Completed) LT (Prematurely Ended) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004713-15 Sponsor Protocol Number: 1235-SR-1005 Start Date*: 2006-02-02
    Sponsor Name:Cardiome Pharma Corp.
    Full Title: A Pilot Phase II, Randomised, Double-blind, Placebo-controlled, Multi-centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flut...
    Medical condition: Atrial fibrillation is the most common arrhythmia encountered in clinical practice. Atrial fibrillation is usually associated with age and general physical condition, rather than with a specific ca...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-014096-46 Sponsor Protocol Number: P090402 Start Date*: 2009-10-12
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Essai thérapeutique de phase IIa ouvert, multicentrique, évaluant l'intérêt du Pazopanib dans les dermatofibrosarcomes de Darier-ferrand (DFSP) inopérables ou localement avancés (intervention mutil...
    Medical condition: Dermatofibrosarcome protubérant (DFSP) ou sarcome de Darrier-Ferrand.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057070 Dermatofibrosarcome protubérant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007784-16 Sponsor Protocol Number: IL1T-GA-0815 Start Date*: 2010-01-05
    Sponsor Name:Regeneron Pharmaceuticals Inc.
    Full Title: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial of the Safety of Rilonacept for the Prophylaxis of Gout Flares in Patients on Urate Lowering Therapy.
    Medical condition: Gout flares
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064900 Gout flare LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002259-15 Sponsor Protocol Number: PCB305/04 Start Date*: 2005-01-24
    Sponsor Name:Photocure ASA
    Full Title: A RANDOMIZED, COMPARATIVE,CONTROLLED PHASE III, MULTICENTER STUDY OF HEXVIX FLUORESCENCE CYSTOSCOPY ANDWHITE LIGHT CYSTOSCOPY IN THE DETECTION OF PAPILLARY BLADDER CANCER AND THE EARLYRECURRENCE RA...
    Medical condition: Malignant neoplasm of bladder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10046518 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005703-42 Sponsor Protocol Number: TMT106468 Start Date*: 2006-03-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 12 week, randomised, double blind study evaluating the effects of low dose (10mg) and high dose (80mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by Ultra s...
    Medical condition: Atherosclerotic Carotid Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:28:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA